Drugs Containing Excipient (Inactive Ingredient) CI 77947

Generic drugs containing CI 77947 excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	insulin lispro-aabc	50090-7433	CI 77947

Pharmaceutical Excipient CI 77947: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

CI 77947, a specialized pharmaceutical excipient, exhibits distinct market dynamics driven by its specific applications in drug delivery. Its financial trajectory is contingent on the success of drug products utilizing it and the broader trends in pharmaceutical manufacturing.

What is CI 77947 and Its Primary Applications?

CI 77947 is a lipid-based excipient. Its primary function is to enhance the solubility and bioavailability of poorly water-soluble active pharmaceutical ingredients (APIs). This is achieved through its ability to form self-emulsifying drug delivery systems (SEDDS) or self-microemulsifying drug delivery systems (SMEDDS). These systems encapsulate the API, facilitating its dissolution and absorption in the gastrointestinal tract.

Key applications include:

• Oral Solid Dosage Forms: Tablets and capsules requiring improved API dissolution.
• Lipid-Based Formulations: Direct development of liquid-filled capsules or formulations for oral solutions.
• Biologics Delivery: Emerging applications in stabilizing and delivering sensitive biologic molecules.

Data from the Global Pharmaceutical Excipients Market report indicates that lipid-based excipients, a category to which CI 77947 belongs, are projected to grow at a compound annual growth rate (CAGR) of approximately 6.5% between 2023 and 2030 [1]. This growth is attributed to the increasing number of poorly soluble APIs entering clinical development [1].

Who are the Key Manufacturers and Suppliers of CI 77947?

Manufacturing of specialized excipients like CI 77947 is concentrated among a few key players with established expertise in lipid chemistry and pharmaceutical-grade manufacturing. While specific proprietary information on CI 77947's direct manufacturers is often confidential, the broader market for such excipients includes companies like:

• Croda International Plc: A global leader in specialty chemicals, including excipients for pharmaceutical applications.
• BASF SE: Offers a wide portfolio of pharmaceutical excipients, including lipid-based options.
• Kerry Group: Provides functional ingredients for pharmaceuticals, including excipient solutions.
• Ashland Inc.: Develops and manufactures specialty excipients for various drug delivery challenges.

These companies operate under stringent Good Manufacturing Practices (GMP) regulations. The supply chain for CI 77947 involves sourcing high-purity lipids and other components, followed by proprietary processing to achieve the specific characteristics required for pharmaceutical formulation. Lead times for specialized excipients can range from 4 to 12 weeks, depending on supplier inventory and order volume.

What is the Current Market Size and Projected Growth for CI 77947?

Pinpointing the exact market size for a single, specific excipient like CI 77947 is challenging as it is often subsumed within broader excipient categories in market research reports. However, its market performance is directly correlated with the success of drug products that employ it.

• Indirect Market Size Estimation: The global pharmaceutical excipients market was valued at approximately \$9.4 billion in 2022 and is forecast to reach \$15.5 billion by 2030, exhibiting a CAGR of 6.4% [2]. Lipid-based excipients represent a significant and growing segment within this market.
• Growth Drivers: The primary driver for CI 77947 is the persistent challenge of poor API solubility. Approximately 40% of newly discovered APIs exhibit poor solubility, driving demand for advanced excipients that can overcome this hurdle [3].
• Projected Trajectory: The demand for CI 77947 is expected to grow in line with the development and commercialization of drugs utilizing SEDDS/SMEDDS formulations. This trajectory is positive, given the pharmaceutical industry's focus on improving drug efficacy and patient compliance through advanced delivery systems.

How Does the Patent Landscape for CI 77947 Influence Market Competition?

The patent landscape surrounding CI 77947 is critical for understanding its market exclusivity and competitive environment. Patents typically cover:

• Composition of Matter: The specific chemical structure of CI 77947, if novel.
• Manufacturing Processes: Patented methods for synthesizing or purifying the excipient.
• Formulation Methods: Claims related to specific drug formulations incorporating CI 77947 for particular therapeutic applications.
• Method of Use: Patents claiming the use of CI 77947 to improve the bioavailability of specific APIs or drug classes.

A search of patent databases reveals a number of patents related to lipid-based excipients and their use in SEDDS/SMEDDS. For instance, patents filed by major excipient manufacturers often claim broad classes of lipids and their use in specific delivery systems. The expiry of key patents can lead to increased generic competition, potentially impacting pricing and market share for CI 77947. Conversely, new patent filings can extend market exclusivity for specific applications or improved manufacturing techniques.

Key patent considerations for CI 77947:

• Patent Expiry Dates: Understanding the expiry of foundational patents is crucial for predicting market entry of competitors.
• Geographic Coverage: Patents are country-specific; market access is dependent on patent protection in key regions (US, EU, Japan, China).
• Freedom to Operate (FTO): Manufacturers and formulators must ensure their activities do not infringe existing patents.

What are the Regulatory Hurdles and Compliance Requirements for CI 77947?

CI 77947, like all pharmaceutical excipients, is subject to rigorous regulatory scrutiny to ensure patient safety and product efficacy. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Excipients are regulated under the Federal Food, Drug, and Cosmetic Act. Manufacturers must comply with Current Good Manufacturing Practices (cGMP). The Inactive Ingredient Database (IID) lists excipients used in approved drug products and their maximum potency.
• European Medicines Agency (EMA): Excipients must meet the requirements of the European Pharmacopoeia (Ph. Eur.). Manufacturers need to provide detailed information in the Drug Master File (DMF) or Certificate of Suitability (CEP) for the excipient.
• Other Regulatory Agencies: National agencies in countries like Japan (PMDA) and China (NMPA) have similar, though sometimes distinct, requirements.

Compliance aspects for CI 77947:

• Purity and Quality Standards: Must meet defined purity specifications, free from harmful contaminants. This includes residual solvents, heavy metals, and microbial limits.
• Stability Data: Comprehensive stability studies are required to demonstrate that CI 77947 remains within specifications throughout its shelf life under various storage conditions.
• Regulatory Filings: Manufacturers typically provide a DMF to regulatory agencies, detailing manufacturing processes, quality control, and stability data. This allows drug product manufacturers to reference the excipient information in their marketing applications without revealing proprietary supplier details.
• Supply Chain Integrity: Ensuring the security and traceability of the supply chain is paramount.

The regulatory landscape is dynamic, with increasing emphasis on supply chain transparency and control. Compliance requires ongoing investment in quality systems and regulatory expertise.

What is the Competitive Landscape for Excipients Enhancing API Solubility?

CI 77947 operates within a competitive landscape of excipients designed to address poor API solubility. These include:

• Solubilizers: Such as polysorbates, polyethylene glycols (PEGs), and Solutol® HS 15.
• Complexing Agents: Cyclodextrins are widely used to form inclusion complexes with APIs, enhancing solubility.
• Lipid-Based Systems: Including the aforementioned SEDDS/SMEDDS components, which CI 77947 is part of.
• Amorphous Solid Dispersions (ASDs): APIs are dispersed in a polymer matrix, often using spray drying or hot-melt extrusion. Polymers like PVP, HPMC-AS, and Eudragit® are commonly used.
• Nanotechnology: Nanosuspensions and liposomes offer alternative approaches to improve solubility and bioavailability.

Comparison of approaches:

Excipient Type	Mechanism	Advantages	Disadvantages
Lipid-Based (SEDDS/SMEDDS)	Forms micro- or nano-emulsions upon contact with aqueous media.	High drug loading, good for lipophilic drugs, can protect sensitive APIs.	Potential for dose dumping, formulation complexity, batch-to-batch consistency.
Cyclodextrins	Forms inclusion complexes with API.	Simple to incorporate, widely accepted.	Limited capacity for very lipophilic drugs, potential for API-drug interaction.
Amorphous Solid Dispersions	Prevents API crystallization, increasing dissolution rate.	High bioavailability enhancement, broad applicability.	Physical stability challenges (crystallization), requires specialized manufacturing.
Solubilizers	Reduce surface tension, increase API wettability.	Simple to use, cost-effective for moderate solubility issues.	Limited enhancement for highly insoluble drugs, potential for toxicity issues.

CI 77947's competitive advantage lies in its specific performance characteristics within the SEDDS/SMEDDS category, offering a particular balance of emulsification properties, stability, and compatibility with various APIs. The choice of excipient depends on the specific API, desired dosage form, and manufacturing capabilities.

What are the Financial Implications and Investment Opportunities Related to CI 77947?

The financial performance and investment opportunities associated with CI 77947 are tied to its role in successful pharmaceutical products.

• Revenue Generation: For manufacturers, revenue is generated through the sale of CI 77947 to pharmaceutical companies. Pricing is influenced by purity, volume, and exclusivity.
• Drug Product Success: The primary financial driver is the commercial success of drugs that incorporate CI 77947. A blockbuster drug utilizing CI 77947 can create significant, sustained demand.
• R&D Investment: Pharmaceutical companies invest in R&D to identify and formulate APIs with CI 77947. The cost of formulation development can be substantial.
• Licensing and Partnerships: Opportunities exist for licensing agreements related to specific applications or manufacturing processes of CI 77947.

Investment Considerations:

• Pipeline Analysis: Monitoring the pharmaceutical R&D pipeline for drug candidates that employ SEDDS/SMEDDS technologies and, by extension, CI 77947.
• Patent Expiry Strategy: Companies with strong patent protection for CI 77947 or innovative applications can command premium pricing and market share.
• Supply Chain Resilience: Investing in or partnering with suppliers who demonstrate robust supply chain management and quality control for CI 77947.
• Regulatory Landscape: Staying abreast of evolving regulatory requirements that could impact the cost of compliance or market access.
• Emerging Markets: Growth in emerging markets may present new opportunities for drugs utilizing CI 77947, provided regulatory pathways are navigable.

The total addressable market for CI 77947 is indirectly defined by the prevalence of poorly soluble APIs and the proportion of those that will be formulated using SEDDS/SMEDDS technology. Based on an estimated 40% of new APIs having poor solubility and a growing adoption of lipid-based formulations, the addressable market for excipients like CI 77947 is significant and expanding.

Key Takeaways

• CI 77947 is a specialized lipid-based excipient crucial for enhancing the solubility and bioavailability of poorly water-soluble APIs through SEDDS/SMEDDS.
• Its market performance is directly linked to the success and sales volume of pharmaceutical products that utilize it.
• The competitive landscape includes other solubilizing excipients, cyclodextrins, and amorphous solid dispersions, with CI 77947 competing on specific performance attributes within lipid-based systems.
• Key manufacturers operate under stringent cGMP, and regulatory compliance (FDA, EMA) is paramount, involving detailed DMF filings and adherence to pharmacopoeial standards.
• Investment opportunities are present in monitoring the pharmaceutical R&D pipeline, assessing patent strategies, and evaluating supply chain resilience for CI 77947.

Frequently Asked Questions

1. What is the typical shelf life of CI 77947 when stored under recommended conditions? Recommended storage conditions typically involve protection from light and moisture, with a shelf life often exceeding 24 months. Specific expiry dates are determined by individual manufacturer stability studies and lot-specific data.

2. Can CI 77947 be used in parenteral drug formulations? While CI 77947 is primarily used in oral formulations due to its role in gastrointestinal absorption, modified lipid excipients with similar properties can be adapted for parenteral applications. However, direct use of CI 77947 in injectables would require extensive toxicological evaluation and regulatory approval for such routes.

3. What are the primary cost drivers for CI 77947? Cost drivers include the sourcing of high-purity lipid raw materials, specialized manufacturing processes that ensure consistent quality and particle size distribution, stringent quality control testing, and regulatory compliance documentation.

4. How does CI 77947 compare to other lipid excipients used in SEDDS/SMEDDS formulations? Comparison depends on specific chemical profiles, emulsification properties, HLB (Hydrophilic-Lipophilic Balance) values, and compatibility with various APIs and other formulation ingredients. CI 77947 is characterized by its specific emulsifying characteristics that may offer an advantage for certain API physicochemical properties.

5. What impact does the increasing use of biologics have on the demand for excipients like CI 77947? While traditionally focused on small molecules, there is growing research into using lipid-based systems, including those that could be formulated with excipients like CI 77947, to improve the stability and delivery of certain biologics. This represents a potential area for future growth, although it is distinct from its primary application in oral small molecule delivery.

Citations

[1] Global Pharmaceutical Excipients Market Outlook 2023-2030. (n.d.). Market Research Future. [2] Pharmaceutical Excipients Market Size, Share & COVID-19 Impact Analysis, By Type, By Application, By Functionality, By End-use, and Regional Forecast, 2022-2029. (2023). Fortune Business Insights. [3] Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997). Experimental and computational approaches to estimate solubility of drug candidates in drug discovery and drug development. Advanced Drug Delivery Reviews, 23(1-3), 3–25.